Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MEDPLUS.NS Stock Summary
Top 10 Correlated ETFs
MEDPLUS.NS
In the News
MEDPLUS.NS Financial details
Company Rating
Buy
Market Cap
81.99B
Income
586.59M
Revenue
53.87B
Book val./share
129.51
Cash/share
16.64
Dividend
-
Dividend %
-
Employees
19.63K
Optionable
No
Shortable
Yes
Earnings
05 Feb 2024
P/E
151.75
Forward P/E
72.25
PEG
-33.7
P/S
1.72
P/B
5.81
P/C
41.34
P/FCF
400.15
Quick Ratio
0.44
Current Ratio
2.87
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
4.7
EPS next Y
9.52
EPS next Q
-
EPS this Y
-51.23%
EPS next Y
102.64%
EPS next 5Y
-
EPS last 5Y
33.05%
Revenue last 5Y
15.07%
Revenue Q/Q
2.33%
EPS Q/Q
-5.74%
-
-
-
-
SMA20
-2.71%
SMA50
-8.34%
SMA100
-14.77%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
4%
ROC
0.06%
Gross Margin
22%
Oper. Margin
3%
Profit Margin
1%
Payout
-
Shs Outstand
119.31M
Shs Float
45.96M
-
-
-
-
Target Price
-
52W Range
598.6-978.0
52W High
-29.67%
52W Low
+15.03%
RSI
52
Rel Volume
2.09
Avg Volume
192.12K
Volume
401.86K
Perf Week
1.93%
Perf Month
14.08%
Perf Quarter
-9.68%
Perf Half Y
-9.65%
-
-
-
-
Beta
0.873
-
-
Volatility
2.37%, 15.09%
Prev Close
0.41%
Price
687.85
Change
1.1%
MEDPLUS.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 189.33 | 238.99 | 255.71 | 335.17 | 382.01 | |
Net income per share | 1 | 0.18 | 5.35 | 8.55 | 4.17 | |
Operating cash flow per share | 12.29 | -0.55 | 0.24 | 15.16 | 7.58 | |
Free cash flow per share | 10.47 | -3.08 | -4.31 | 4.66 | -6.59 | |
Cash per share | 4.18 | 11.81 | 12.5 | 58.69 | 24.82 | |
Book value per share | 24.42 | 44.24 | 61.23 | 126.54 | 124.99 | |
Tangible book value per share | 20.85 | 40.54 | 57.49 | 122.23 | 120.83 | |
Share holders equity per share | 24.42 | 44.24 | 61.23 | 126.54 | 124.99 | |
Interest debt per share | 39.94 | 43.87 | 53.96 | 78.66 | 82.39 | |
Market cap | 133.76B | 133.76B | 133.76B | 113.67B | 77.51B | |
Enterprise value | 137.79B | 137.39B | 138.59B | 121.6B | 84.23B | |
P/E ratio | 1.12K | 6.14K | 209.46 | 118.65 | 155.76 | |
Price to sales ratio | 5.92 | 4.69 | 4.38 | 3.03 | 1.7 | |
POCF ratio | 91.19 | -2.03K | 4.63K | 66.91 | 85.73 | |
PFCF ratio | 107.07 | -363.48 | -260.4 | 217.89 | -98.62 | |
P/B Ratio | 45.91 | 25.34 | 18.31 | 8.02 | 5.2 | |
PTB ratio | 45.91 | 25.34 | 18.31 | 8.02 | 5.2 | |
EV to sales | 6.1 | 4.82 | 4.54 | 3.24 | 1.85 | |
Enterprise value over EBITDA | 105.48 | 75.3 | 59.07 | 40.53 | 26.98 | |
EV to operating cash flow | 93.94 | -2.09K | 4.79K | 71.58 | 93.16 | |
EV to free cash flow | 110.3 | -373.35 | -269.81 | 233.1 | -107.17 | |
Earnings yield | 0 | 0 | 0 | 0.01 | 0.01 | |
Free cash flow yield | 0.01 | 0 | 0 | 0 | -0.01 | |
Debt to equity | 1.47 | 0.9 | 0.81 | 0.57 | 0.6 | |
Debt to assets | 0.45 | 0.35 | 0.38 | 0.31 | 0.32 | |
Net debt to EBITDA | 3.09 | 1.99 | 2.06 | 2.64 | 2.15 | |
Current ratio | 1.26 | 1.7 | 2.22 | 2.92 | 3.11 | |
Interest coverage | 1.29 | 2.1 | 2.52 | 2.45 | 1.16 | |
Income quality | 6.45 | -0.22 | 0.03 | 1.44 | 1.92 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.01 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | |
Capex to operating cash flow | -0.15 | 4.59 | -18.77 | -0.69 | -1.87 | |
Capex to revenue | -0.01 | -0.01 | -0.02 | -0.03 | -0.04 | |
Capex to depreciation | -0.37 | -0.4 | -0.61 | -0.99 | -0.93 | |
Stock based compensation to revenue | 0 | 0 | 0.01 | 0 | 0 | |
Graham number | 23.43 | 13.49 | 85.87 | 156.02 | 108.3 | |
ROIC | 0.03 | 0 | 0.05 | 0.04 | 0.03 | |
Return on tangible assets | 0.01 | 0 | 0.04 | 0.04 | 0.02 | |
Graham Net | -33.69 | -29.51 | -25.68 | -5.11 | -36.17 | |
Working capital | 971.98M | 3.35B | 5.08B | 10.73B | 10.04B | |
Tangible asset value | 2.49B | 4.84B | 6.86B | 13.7B | 14.42B | |
Net current asset value | -1.98B | -38.17M | 885.22M | 4.55B | 1.75B | |
Invested capital | 1.47 | 0.9 | 0.81 | 0.57 | 0.6 | |
Average receivables | 0 | 155.3M | 58.84M | 57.02M | 73.44M | |
Average payables | 0 | 1.96B | 1.91B | 1.97B | 2.53B | |
Average inventory | 0 | 5.19B | 6.97B | 8.32B | 10.3B | |
Days sales outstanding | 3.98 | 0.82 | 0.64 | 0.59 | 0.69 | |
Days payables outstanding | 31.28 | 36.56 | 22.29 | 30.14 | 26.69 | |
Days of inventory on hand | 77.95 | 100.48 | 112.88 | 111.98 | 117.38 | |
Receivables turnover | 91.6 | 445.51 | 568.43 | 622.16 | 526.83 | |
Payables turnover | 11.67 | 9.98 | 16.37 | 12.11 | 13.68 | |
Inventory turnover | 4.68 | 3.63 | 3.23 | 3.26 | 3.11 | |
ROE | 0.04 | 0 | 0.09 | 0.07 | 0.03 | |
Capex per share | -1.82 | -2.53 | -4.55 | -10.51 | -14.17 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 100.12 | 80.63 | 108.55 | 117.99 | 120.77 | |
Net income per share | 1.13 | 1.71 | 0.32 | 1.22 | 1.15 | |
Operating cash flow per share | 7.7 | 1.42 | 8.86 | 9.29 | 9.57 | |
Free cash flow per share | 7.7 | 1.42 | 8.86 | 9.29 | 9.57 | |
Cash per share | 96.34 | 19.06 | 71.18 | 19.11 | 16.64 | |
Book value per share | 122.83 | 95.96 | 126.72 | 127.55 | 129.51 | |
Tangible book value per share | 122.83 | 92.76 | 126.72 | 123.26 | 129.51 | |
Share holders equity per share | 122.83 | 95.96 | 126.72 | 127.55 | 129.51 | |
Interest debt per share | 1.79 | 59.34 | 1.97 | 82.23 | 2.05 | |
Market cap | 72.95B | 100.96B | 91.68B | 91.78B | 88.4B | |
Enterprise value | 69.76B | 107.68B | 89.18B | 100.16B | 86.41B | |
P/E ratio | 136.03 | 94.95 | 605.39 | 157.55 | 161 | |
Price to sales ratio | 6.13 | 8.06 | 7.14 | 6.52 | 6.13 | |
POCF ratio | 79.66 | 456.45 | 87.46 | 82.73 | 77.39 | |
PFCF ratio | 79.66 | 456.45 | 87.46 | 82.73 | 77.39 | |
P/B Ratio | 5 | 6.77 | 6.12 | 6.03 | 5.72 | |
PTB ratio | 5 | 6.77 | 6.12 | 6.03 | 5.72 | |
EV to sales | 5.86 | 8.59 | 6.94 | 7.11 | 5.99 | |
Enterprise value over EBITDA | 83.97 | 112.96 | 110.46 | 104.93 | 85.07 | |
EV to operating cash flow | 76.18 | 486.81 | 85.07 | 90.28 | 75.65 | |
EV to free cash flow | 76.18 | 486.81 | 85.07 | 90.28 | 75.65 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
Debt to equity | 0 | 0.6 | 0 | 0.63 | 0 | |
Debt to assets | 0 | 0.32 | 0 | 0.33 | 0 | |
Net debt to EBITDA | -3.83 | 7.05 | -3.1 | 8.78 | -1.96 | |
Current ratio | 3.12 | 3.11 | 3.09 | 2.87 | 2.93 | |
Interest coverage | 1.77 | 1.77 | 0.81 | 1.7 | 1.81 | |
Income quality | 6.83 | 0.83 | 27.69 | 7.62 | 8.32 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0.03 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0.02 | 0 | 0.02 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0.02 | 0 | 0 | 0 | |
Graham number | 55.83 | 60.77 | 30.21 | 59.17 | 57.89 | |
ROIC | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | |
Return on tangible assets | 0 | 0.01 | 0 | 0.01 | 0 | |
Graham Net | 35.65 | -27.77 | 7.06 | -45.5 | -48.21 | |
Working capital | 10.09B | 10.04B | 10.12B | 10.17B | 10.45B | |
Tangible asset value | 14.6B | 14.42B | 14.99B | 14.71B | 15.46B | |
Net current asset value | 2.21B | 1.75B | 1.46B | 1.46B | 1.54B | |
Invested capital | 0 | 0.6 | 0 | 0.63 | 0 | |
Average receivables | 35.61M | 43.26M | 43.26M | 44.16M | 44.16M | |
Average payables | 2.84B | 2.73B | 2.61B | 2.81B | 3B | |
Average inventory | 10.52B | 11.15B | 11.65B | 12.31B | 12.96B | |
Days sales outstanding | 0 | 0.62 | 0 | 0.56 | 0 | |
Days payables outstanding | 27.7 | 24.14 | 23.31 | 24.43 | 24.09 | |
Days of inventory on hand | 105.58 | 106.15 | 105.6 | 103.92 | 105.59 | |
Receivables turnover | 0 | 144.84 | 0 | 159.51 | 0 | |
Payables turnover | 3.25 | 3.73 | 3.86 | 3.68 | 3.74 | |
Inventory turnover | 0.85 | 0.85 | 0.85 | 0.87 | 0.85 | |
ROE | 0.01 | 0.02 | 0 | 0.01 | 0.01 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
MEDPLUS.NS Frequently Asked Questions
What is MedPlus Health Services Limited stock symbol ?
MedPlus Health Services Limited is a IN stock and trading under the symbol MEDPLUS.NS
What is MedPlus Health Services Limited stock quote today ?
MedPlus Health Services Limited stock price is $687.85 today.
Is MedPlus Health Services Limited stock public?
Yes, MedPlus Health Services Limited is a publicly traded company.